scholarly journals Gamma Knife radiosurgery for brain metastases in non-small cell lung cancer patients treated with immunotherapy or targeted therapy

2021 ◽  
Vol 1 ◽  
pp. 100699
Author(s):  
A. Cho ◽  
H. Untersteiner ◽  
D. Hirschmann ◽  
A. Shaltout ◽  
P. Göbl ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3668
Author(s):  
Anna Cho ◽  
Helena Untersteiner ◽  
Dorian Hirschmann ◽  
Abdallah Shaltout ◽  
Philipp Göbl ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Gamma Knife ◽  
Cell Lung Cancer ◽  
Combined Treatment ◽  
Gamma Knife Radiosurgery ◽  
Small Cell ◽  
Small Cell Lung

The combination of Gamma Knife radiosurgery (GKRS) and systemic immunotherapy (IT) or targeted therapy (TT) is a novel treatment method for brain metastases (BMs) in non-small cell lung cancer (NSCLC). To elucidate the safety and efficacy of concomitant IT or TT on the outcome after GKRS, 496 NSCLC patients with BMs, who were treated with GKRS were retrospectively reviewed. The median time between the initial lung cancer diagnosis and the diagnosis of brain metastases was one month. The survival after the initial BM diagnosis was significantly longer than the survival predicted by prognostic BM scores. After the first Gamma Knife radiosurgery treatment (GKRS1), the estimated median survival was 9.9 months (95% CI = 8.3–11.4). Patients with concurrent IT or TT presented with a significantly longer survival after GKRS1 than patients without IT or TT (p < 0.001). These significant differences in the survival were also apparent among the four treatment groups and remained significant after adjustment for Karnofsky performance status scale (KPS), recursive partitioning analysis (RPA) class, sex, and multiple BMs. About half of all our patients (46%) developed new distant BMs after GKRS1. Of note, no statistically significant differences in the occurrence of radiation reaction, radiation necrosis, or intralesional hemorrhage in association with IT or TT at or after GKRS1 were observed. In NSCLC-BM patients, the concomitant use of GKRS and IT or TT showed an increase in overall survival without increased complications related to GKRS. Therefore, the combined treatment with GKRS and IT or TT seems to be a safe and powerful treatment option and emphasizes the role of radiosurgery in modern BM treatment.

Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases

Lung Cancer ◽  
2018 ◽  
Vol 125 ◽  
pp. 8-13 ◽  
Author(s):  
Kaiyan Chen ◽  
Xiaoqing Yu ◽  
Fanrong Zhang ◽  
Yanjun Xu ◽  
Peng Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Gene Alterations

scholarly journals Integrated genomic and DNA methylation analyses of non-small cell lung cancer patients with brain metastases

2019 ◽  
Vol 30 ◽  
pp. v602-v603
Author(s):  
Y. Fan ◽  
Y. Xu ◽  
Z. Huang ◽  
K. Chen ◽  
H. Han-Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Methylation ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases

2016 ◽  
Vol 12 (6) ◽  
pp. 4635-4642 ◽  
Author(s):  
Dimitra Stefanou ◽  
Sofia Stamatopoulou ◽  
Antigoni Sakellaropoulou ◽  
Gavriil Akakios ◽  
Marina Gkiaouraki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Treatment

Frequent overexpression of ErbB - receptor family members in brain metastases of non-small cell lung cancer patients

Apmis ◽  
2013 ◽  
Vol 121 (12) ◽  
pp. 1144-1152 ◽  
Author(s):  
Anna Sophie Berghoff ◽  
Manuel Magerle ◽  
Ayseguel Ilhan-Mutlu ◽  
Carina Dinhof ◽  
Georg Widhalm ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Erbb Receptor ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Erbb Receptor Family ◽  
Receptor Family
Sign in / Sign up

Export Citation Format

Share Document